The Medicines and Healthcare products Regulatory Agency said it has approved Zurzuvae to treat moderate or severe postnatal depression in adults following childbirth. Zuranolone is the first oral treatment for postnatal depression approved in the UK, the agency said in a statement. The approval was granted to Biogen (BIIB).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen, Stoke Therapeutics present data from studies of zorevunersen
- Eisai and Biogen launch Leqembi in Austria, Germany
- Biogen’s Innovative Study on Litifilimab Delivery: Market Implications and Study Insights
- Biogen’s Phase 3 Study on Felzartamab: A Potential Game-Changer for IgA Nephropathy
- Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment?